Cipla, a global pharmaceutical company, and Kemwell Biopharma, a biopharmaceutical contract development and manufacturing organization (CDMO), have entered a joint venture agreement to develop, manufacture and commercialize biosimilars for global markets. A joint venture company will be incorporated with an aim to enter the respiratory biosimilars space.
 
The joint venture will leverage Cipla and Kemwell’s complementary strengths for end-to-end product development, clinical development, regulatory filings, manufacturing and commercialization of biopharmceutical products. Cipla’s respiratory prowess combined with Kemwell’s expertise in biologics will accelerate bringing these products to market.
 
“This development reinforces our strength as leaders in respiratory therapy and is in line with our aspiration of global lung leadership,” said Umang Vohra, managing director global CEO of Cipla. “Guided by our purpose of ‘Caring for life’ our partnership with Kemwell will help serve unmet needs of patients across the globe.”
 
Anurag Bagaria, chairman and CEO of Kemwell, said, “We are very excited about combining the strengths of Cipla’s expertise in development and commercialization of respiratory products and Kemwell’s biologics capabilities. Through this joint venture, we aim to make cost-effective biotherapeutics available to more patients globally.”